North America Tuberculosis Diagnostics Market Size, Share & Trends Analysis Report By End Use (Diagnostic Laboratories, Hospitals & Clinics, and Others), By Type, By Country and Growth Forecast, 2024 - 2031

The North America Tuberculosis Diagnostics Market would witness market growth of 4.1% CAGR during the forecast period (2024-2031).

The US market dominated the North America Tuberculosis Diagnostics Market by Country in 2023, and would continue to be a dominant market till 2031; thereby, achieving a market value of $635.4 million by 2031. The Canada market is experiencing a CAGR of 6.3% during (2024 - 2031). Additionally, The Mexico market would exhibit a CAGR of 5.4% during (2024 - 2031).

The market represents a critical segment of the healthcare industry, as the fight against tuberculosis (TB) remains a top public health priority. Mycobacterium tuberculosis is the causative agent of tuberculosis, an infectious disease that attacks the lungs as its primary site of infection. Despite the fact that it is both preventable and curable, tuberculosis continues to be one of the leading causes of death, particularly in countries with poor and middle incomes.

Digital platforms can facilitate the collection and sharing of diagnostic data across healthcare systems, improving coordination and ensuring patients receive appropriate care throughout their treatment journey. In order to develop diagnostic instruments that are both adaptable and effective in a variety of healthcare environments, companies are increasingly investing in research and development. This focus on innovation is essential for overcoming the challenges associated with TB diagnosis and ensuring that all patients, regardless of where they live, have access to the best possible care.

In Mexico, the rising demand for tuberculosis diagnostics is influenced by the country’s efforts to combat TB in regions with high poverty levels and inadequate healthcare infrastructure. In 2021, there were 17 new tuberculosis cases per 100,000 population in Mexico. In 2019, the overall tuberculosis mortality rate (age-adjusted and per 100,000 population) was 1.6 (0.9 in women and 2.4 in men). The nation has been striving to incorporate more sophisticated diagnostic methods, including molecular tests and rapid diagnostic tools, into its national tuberculosis program, with a particular emphasis on rural and underserved regions where conventional diagnostic methods may not be adequate. Thus, the North American market is poised for continued growth as these nations intensify their efforts to eliminate tuberculosis and address the specific needs of their populations.

Free Valuable Insights: The Tuberculosis Diagnostics Market is Predict to reach USD 3.0 Billion by 2031, at a CAGR of 4.7%

Based on End Use, the market is segmented into Diagnostic Laboratories, Hospitals & Clinics, and Others. Based on Type, the market is segmented into Detection of Latent Infection (Skin Test & IGRA), Phage Assay, Detection of Drug Resistance (DST), Nucleic Acid Testing, Radiographic Method, Cytokine Detection Assay, Diagnostic Laboratory Methods, and Other Methods. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.

List of Key Companies Profiled

• Abbott Laboratories
• Qiagen N.V
• Thermo Fisher Scientific Inc.
• Becton, Dickinson and Company
• F.Hoffmann-La Roche Ltd.
• Hologic, Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• Bruker Corporation

North America Tuberculosis Diagnostics Market Report Segmentation

By End Use

• Diagnostic Laboratories
• Hospitals & Clinics
• Others

By Type

• Detection of Latent Infection (Skin Test & IGRA)
• Phage Assay
• Detection of Drug Resistance (DST)
• Nucleic Acid Testing
• Radiographic Method
• Cytokine Detection Assay
• Diagnostic Laboratory Methods
• Other Methods

By Country

• US
• Canada
• Mexico
• Rest of North America

Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Tuberculosis Diagnostics Market, by End Use
1.4.2 North America Tuberculosis Diagnostics Market, by Type
1.4.3 North America Tuberculosis Diagnostics Market, by Country
1.5 Methodology for the research

Chapter 2. Market at a Glance
2.1 Key Highlights

Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.2.3 Market Opportunities
3.2.4 Market Challenges
3.3 Porter Five Forces Analysis

Chapter 4. North America Tuberculosis Diagnostics Market by End Use
4.1 North America Diagnostic Laboratories Market by Country
4.2 North America Hospitals & Clinics Market by Country
4.3 North America Others Market by Country

Chapter 5. North America Tuberculosis Diagnostics Market by Type
5.1 North America Detection of Latent Infection (Skin Test & IGRA) Market by Country
5.2 North America Phage Assay Market by Country
5.3 North America Detection of Drug Resistance (DST) Market by Country
5.4 North America Nucleic Acid Testing Market by Country
5.5 North America Radiographic Method Market by Country
5.6 North America Cytokine Detection Assay Market by Country
5.7 North America Diagnostic Laboratory Methods Market by Country
5.8 North America Other Methods Market by Country

Chapter 6. North America Tuberculosis Diagnostics Market by Country
6.1 US Tuberculosis Diagnostics Market
6.1.1 US Tuberculosis Diagnostics Market by End Use
6.1.2 US Tuberculosis Diagnostics Market by Type
6.2 Canada Tuberculosis Diagnostics Market
6.2.1 Canada Tuberculosis Diagnostics Market by End Use
6.2.2 Canada Tuberculosis Diagnostics Market by Type
6.3 Mexico Tuberculosis Diagnostics Market
6.3.1 Mexico Tuberculosis Diagnostics Market by End Use
6.3.2 Mexico Tuberculosis Diagnostics Market by Type
6.4 Rest of North America Tuberculosis Diagnostics Market
6.4.1 Rest of North America Tuberculosis Diagnostics Market by End Use
6.4.2 Rest of North America Tuberculosis Diagnostics Market by Type

Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Qiagen N.V.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.2.6 SWOT Analysis
7.3 Thermo Fisher Scientific, Inc.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expenses
7.3.5 Recent strategies and developments:
7.3.5.1 Product Launches and Product Expansions:
7.3.6 SWOT Analysis
7.4 Becton, Dickinson, and Company
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.4.5 Recent strategies and developments:
7.4.5.1 Partnerships, Collaborations, and Agreements:
7.4.6 SWOT Analysis
7.5 F. Hoffmann-La Roche Ltd.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Segmental and Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Acquisition and Mergers:
7.5.6 SWOT Analysis
7.6 Hologic, Inc.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Segmental and Regional Analysis
7.6.4 Research & Development Expenses
7.6.5 SWOT Analysis
7.7 Danaher Corporation
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.7.5 SWOT Analysis
7.8 DiaSorin S.p.A.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 SWOT Analysis
7.9 Bruker Corporation
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 SWOT Analysis
7.10. Revvity, Inc.
7.10.1 Company Overview
7.10.2 Financial Analysis
7.10.3 Segmental and Regional Analysis
7.10.4 Research & Development Expenses
7.10.5 SWOT Analysis

TABLE 1 North America Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 2 North America Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 3 North America Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 4 North America Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 5 North America Diagnostic Laboratories Market by Country, 2020 - 2023, USD Million
TABLE 6 North America Diagnostic Laboratories Market by Country, 2024 - 2031, USD Million
TABLE 7 North America Hospitals & Clinics Market by Country, 2020 - 2023, USD Million
TABLE 8 North America Hospitals & Clinics Market by Country, 2024 - 2031, USD Million
TABLE 9 North America Others Market by Country, 2020 - 2023, USD Million
TABLE 10 North America Others Market by Country, 2024 - 2031, USD Million
TABLE 11 North America Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 12 North America Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 13 North America Detection of Latent Infection (Skin Test & IGRA) Market by Country, 2020 - 2023, USD Million
TABLE 14 North America Detection of Latent Infection (Skin Test & IGRA) Market by Country, 2024 - 2031, USD Million
TABLE 15 North America Phage Assay Market by Country, 2020 - 2023, USD Million
TABLE 16 North America Phage Assay Market by Country, 2024 - 2031, USD Million
TABLE 17 North America Detection of Drug Resistance (DST) Market by Country, 2020 - 2023, USD Million
TABLE 18 North America Detection of Drug Resistance (DST) Market by Country, 2024 - 2031, USD Million
TABLE 19 North America Nucleic Acid Testing Market by Country, 2020 - 2023, USD Million
TABLE 20 North America Nucleic Acid Testing Market by Country, 2024 - 2031, USD Million
TABLE 21 North America Radiographic Method Market by Country, 2020 - 2023, USD Million
TABLE 22 North America Radiographic Method Market by Country, 2024 - 2031, USD Million
TABLE 23 North America Cytokine Detection Assay Market by Country, 2020 - 2023, USD Million
TABLE 24 North America Cytokine Detection Assay Market by Country, 2024 - 2031, USD Million
TABLE 25 North America Diagnostic Laboratory Methods Market by Country, 2020 - 2023, USD Million
TABLE 26 North America Diagnostic Laboratory Methods Market by Country, 2024 - 2031, USD Million
TABLE 27 North America Other Methods Market by Country, 2020 - 2023, USD Million
TABLE 28 North America Other Methods Market by Country, 2024 - 2031, USD Million
TABLE 29 North America Tuberculosis Diagnostics Market by Country, 2020 - 2023, USD Million
TABLE 30 North America Tuberculosis Diagnostics Market by Country, 2024 - 2031, USD Million
TABLE 31 US Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 32 US Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 33 US Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 34 US Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 35 US Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 36 US Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 37 Canada Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 38 Canada Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 39 Canada Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 40 Canada Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 41 Canada Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 42 Canada Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 43 Mexico Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 44 Mexico Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 45 Mexico Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 46 Mexico Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 47 Mexico Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 48 Mexico Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 49 Rest of North America Tuberculosis Diagnostics Market, 2020 - 2023, USD Million
TABLE 50 Rest of North America Tuberculosis Diagnostics Market, 2024 - 2031, USD Million
TABLE 51 Rest of North America Tuberculosis Diagnostics Market by End Use, 2020 - 2023, USD Million
TABLE 52 Rest of North America Tuberculosis Diagnostics Market by End Use, 2024 - 2031, USD Million
TABLE 53 Rest of North America Tuberculosis Diagnostics Market by Type, 2020 - 2023, USD Million
TABLE 54 Rest of North America Tuberculosis Diagnostics Market by Type, 2024 - 2031, USD Million
TABLE 55 Key Information – Abbott Laboratories
TABLE 56 Key Information – Qiagen N.V.
TABLE 57 Key Information – Thermo Fisher Scientific, Inc.
TABLE 58 Key Information – Becton, Dickinson and Company
TABLE 59 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 60 Key Information – Hologic, Inc.
TABLE 61 Key Information – Danaher Corporation
TABLE 62 Key Information – DiaSorin S.p.A.
TABLE 63 Key Information – Bruker Corporation
TABLE 64 Key Information – Revvity, Inc.

List of Figures
FIG 1 Methodology for the research
FIG 2 North America Tuberculosis Diagnostics Market, 2020 - 2031, USD Million
FIG 3 Key Factors Impacting Tuberculosis Diagnostics Market
FIG 4 Porter’s Five Forces Analysis – Tuberculosis Diagnostics Market
FIG 5 North America Tuberculosis Diagnostics Market share by End Use, 2023
FIG 6 North America Tuberculosis Diagnostics Market share by End Use, 2031
FIG 7 North America Tuberculosis Diagnostics Market by End Use, 2020 - 2031, USD Million
FIG 8 North America Tuberculosis Diagnostics Market share by Type, 2023
FIG 9 North America Tuberculosis Diagnostics Market share by Type, 2031
FIG 10 North America Tuberculosis Diagnostics Market by Type, 2020 - 2031, USD Million
FIG 11 North America Tuberculosis Diagnostics Market share by Country, 2023
FIG 12 North America Tuberculosis Diagnostics Market share by Country, 2031
FIG 13 North America Tuberculosis Diagnostics Market by Country, 2020 - 2031, USD Million
FIG 14 SWOT Analysis: Abbott Laboratories
FIG 15 Swot Analysis: Qiagen N.V.
FIG 16 SWOT Analysis: Thermo Fisher Scientific, Inc.
FIG 17 SWOT Analysis: Becton, Dickinson and company
FIG 18 SWOT Analysis: F. Hoffmann-La Roche Ltd.
FIG 19 Swot Analysis: Hologic, Inc.
FIG 20 SWOT Analysis: Danaher Corporation
FIG 21 SWOT Analysis: DiaSorin S.p.A.
FIG 22 Swot Analysis: Bruker Corporation
FIG 23 Swot Analysis: Revvity, Inc.